>
Switch to:

PTC Therapeutics ROA %

: -26.29% (As of Sep. 2021)
View and export this data going back to 2013. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. PTC Therapeutics's annualized Net Income for the quarter that ended in Sep. 2021 was $-534.5 Mil. PTC Therapeutics's average Total Assets over the quarter that ended in Sep. 2021 was $2,033.0 Mil. Therefore, PTC Therapeutics's annualized ROA % for the quarter that ended in Sep. 2021 was -26.29%.

The historical rank and industry rank for PTC Therapeutics's ROA % or its related term are showing as below:

NAS:PTCT' s ROA % Range Over the Past 10 Years
Min: -91.7   Med: -31.28   Max: 70
Current: -21.53

-91.7
70

During the past 10 years, PTC Therapeutics's highest ROA % was 70.00%. The lowest was -91.70%. And the median was -31.28%.

NAS:PTCT's ROA % is ranked higher than
62% of the 1496 Companies
in the Biotechnology industry.

( Industry Median: -31.09 vs. NAS:PTCT: -21.53 )

PTC Therapeutics ROA % Historical Data

The historical data trend for PTC Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.79 -23.90 -16.95 -18.34 -22.87

PTC Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.24 -13.55 -23.82 -22.71 -26.29

Competitive Comparison

For the Biotechnology subindustry, PTC Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

PTC Therapeutics ROA % Distribution

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's ROA % falls into.



PTC Therapeutics ROA % Calculation

PTC Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2020 is calculated as:

ROA %=Net Income (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=-438.16/( (1623.782+2208.278)/ 2 )
=-438.16/1916.03
=-22.87 %

PTC Therapeutics's annualized ROA % for the quarter that ended in Sep. 2021 is calculated as:

ROA %=Net Income (Q: Sep. 2021 )/( (Total Assets (Q: Jun. 2021 )+Total Assets (Q: Sep. 2021 ))/ count )
=-534.496/( (2058.669+2007.325)/ 2 )
=-534.496/2032.997
=-26.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2021) net income data. ROA % is displayed in the 30-year financial page.


PTC Therapeutics  (NAS:PTCT) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2021 )
=Net Income/Total Assets
=-534.496/2032.997
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-534.496 / 554.972)*(554.972 / 2032.997)
=Net Margin %*Asset Turnover
=-96.31 %*0.273
=-26.29 %

Note: The Net Income data used here is four times the quarterly (Sep. 2021) net income data. The Revenue data used here is four times the quarterly (Sep. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


PTC Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

PTC Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Southwell David P director C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven director PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter director, officer: Chief Executive Officer PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie officer: SVP, Finance & CAO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn director C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric officer: Chief Business Officer 550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B. officer: Chief Development Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael director 1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio officer: Chief Operating Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory officer: Chief Technical Ops Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma director C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B director 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)